Funds for these opportunities have expired. We are no longer accepting applications.
Translational Opportunity Funds
The LC has a limited amount of funds available for supporting pilot or replication studies that will advance the effort toward the development of drugs that will slow the aging process and improve healthy aging. Study proposals will be generated by investigators working in active consultation with the one of the Consortium’s Working Groups (currently focused on FOXO3 and APOE) or, in some circumstances, directly with members of the Steering Committee. It is expected that the findings from these pilot studies will provide the essential/preliminary data needed for larger and more fully funded NIH or foundation grant applications. Translational Opportunity Funds (TOF) are not to be used to fund work that is appropriate for a R01 application.
Translational opportunity funds are designed to fund pilot studies investigating cellular and molecular mechanisms underlying genetic associations with longevity-related traits, or testing whether findings from the basic science of longevity can be applied to human model systems, e.g., cell culture and/or human genetic associations. Some examples include:
- Examination of chromatin looping between FOXO3 intron 2, which contains longevity-associated variants, and the FOXO3 promoter.
- Replication studies in humans to characterize genetic associations with human lifespan and longevity.
- Chemical screening to find compounds impacting the function of longevity-associated genes.
The list above is not all-inclusive. Pilot studies that could potentially identify novel aspects of the biology of human aging are encouraged. Please contact Dan Evans and Alice LaRocca if you have an idea for a TOF application but are unsure if it would fit within the research scope.
Process for Applying
Please contact Dan Evans for information about applying. We encourage interested applicants to send a specific aims page to Dan and Alice to determine whether the project fits within the TOF research scope. Proposals and funding will be managed and tracked by Alice LaRocca. There are no application deadlines.
The individual serving as PI of the project will generally prepare the proposal. As described more fully below, these proposals will be relatively short but, among other things, should include a rationale for doing the study, a description of methods, anticipated findings and methodological limitations and budget. They should also have the support of the working group or some members of the Steering Committee.
Format of Proposals for Translational Opportunity Funds:
Cover Sheet – including the names of the Principal Investigator, co-investigators (if any), institutional affiliation(s) and contact information.
Summary statement describing the following: 1) how the proposed work would contribute to the goals of the Longevity Consortium and aid in the translation of current research to potential clinical applications, and 2) if the project is funded, how would the PI benefit, does the PI plan to continue the study, and how would the PI use the pilot data for future grant applications. This statement can be prepared in collaboration with Longevity Consortium working group members.
Brief background, rationale, and specific aims
Methods: 1-3 pages. Include statistical analysis methods.
Anticipated findings; limitations in study design, if any
Budget (using NIH budget sheets) and expected timeline of findings.
NIH Biosketches from all key personnel.
Policies and Guidelines
Funding is available for a one year pilot period. Available funding is $100,000 (direct costs). There is no cap on indirect costs. PI salary should be 20% effort or less. Effort levels may be higher for non-PI personnel. Please contact Dan Evans and Alice LaRocca if you plan to deviate from these guidelines.
Submitted proposals will receive an initial review by the Steering Committee within two weeks after they are received and, if approved, will be forwarded to the Outside Monitoring Board (OMB) for recommendations on whether an award should be made. The OMB may invite ad hoc reviewers to assist in the review of proposals.
Ad hoc reviewers, if employed, will have up to four weeks to complete their reviews and, if several or more applications are received concurrently, rank the proposals. The results will then be forwarded to the Steering Committee to finalize decisions and notify applicants. The latter should take no more than 30 days. The decision on whether or not to fund a proposal rests with the Steering Committee.
Eligible applicants are individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Principal Investigator. Eligible organizations include those from public or private higher education institutions, non-profits other than institutions of higher education, for-profit organizations, and foreign institutions. Applications that include collaborations with for-profit organizations are eligible.
It is expected that the findings from these pilot studies will provide the essential/preliminary data needed for larger and more fully funded NIH or foundation grant applications. Translational Opportunity Funds are not to be used to fund work that is appropriate for a R01 application.
In the event that a new proposal raises an issue not covered by existing policies, the Longevity Consortium and the NIA reserve the right to amend existing policies and develop new policies for Translational Opportunity Funds.